, /PRNewswire/ - Kinectrics, a global provider of nuclear lifecycle services announces the first shipments of highly enriched Ytterbium-176 (Yb-176), strengthening the radiopharmaceutical supply chain and reducing reliance on Russian material. No-carrier added Lutetium-177 (n.c.
a. Lu-177) has quickly become an important isotope for therapeutic radiopharmaceuticals. There is growing demand for n.
c.a. Lu-177 due to the expanding pipeline of Lu-177 therapies.
The input material for creating n.c.a.
Lu-177 is Yb-176, a stable isotope that is irradiated in nuclear reactors, producing Lu-177 through neutron activation. "Creating a robust commercial supply of Yb-176 is important to ensure a consistent supply of Lu-177," said , CEO of Kinectrics. "We have invested, through our joint venture company Isogen, in isotope production technology that has been routinely providing Lu-177 deliveries from Bruce Power since fall of 2022.
With our first shipments of Yb-176, we demonstrate that Kinectrics can rapidly advance medical isotope innovations from concept to dependable commercial production." The production of all n.c.
a. Lu-177 depends on a complex and very limited global supply chain which up to now has predominantly been dependent on supply from . Kinectrics is expanding our proven stable isotope production technology through 2024 with the aim to become the largest non-Russian producer of Yb-176.
Following several years of effort to develop and implement novel electromagnetic isotope en.
